Janssen chooses Ghent as location for their first European cell therapy production site

Janssen’s first European state-of-the-art facilities for the production of CAR-T therapy will be located in the Tech Lane Science Park in Ghent. CAR-T (Chimeric antigen receptor T cell therapy) is a specific type of (immune) cell therapy in which a patient’s own T-cells are reprogrammed to attack cancer cells.

The fact that Janssen chooses Ghent as location for their cell therapy production site is a strong recognition of and boost for all immune-oncology research at CRIG.

Read more on the website of Janssen, and in these articles (in Dutch):
-‘J&J kiest Gent als Europese productiesite voor bloedkankertherapie’ – De Tijd
-‘Janssen Pharmaceutica plant grote vestiging voor kankertherapie in Gent: "Veel ruimte en talent in de buurt"' – VRT NWS